Cannabis Science Set to Integrate Its Sponsored Research In Nigeria to Include Its U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurological Conditions

Available Files

No files uploaded.

Robert Kane Monday, 25 February 2019 06:45

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD). CBIS and its research collaborator are currently investigating the potential beneficial effects of cannabidiol on oro-bucco-lingual dyskinesias, oxidative stress, and psychosis using animal studies and a clinical trial. 

See the full press release here;

Loading content, please wait.

Become an iCannabinoid Ambassador


Observational Studies


Activity Stream

John Cochran replied to Stocks 2 hours 53 minutes ago

I am feeling like many of us are being left in the dark.... have there been any announcements in the past 7 days?

John Cochran has liked a Discussion 2 hours 54 minutes ago



Sorry, we currently have no events.
View All Events